Eli Lilly announced Monday morning that it is divesting Baqsimi, its low blood sugar rescue treatment, to Amphastar Pharmaceuticals for $500 million. The boards of directors at both companies have ...

INDIANAPOLIS, IN and RANCHO CUCAMONGA, CA / ACCESSWIRE / April 24, 2023 / In an effort to continue expanding the availability of BAQSIMI® to patients, Eli Lilly and Company (NYSE: LLY) and Amphastar ...

The market opportunity for Baqsimi is promising because only a small fraction of insulin users currently receive a prescription for glucagon Amphastar Pharmaceuticals is keen on exploring business ...

It isn’t known whether Baqsimi (glucagon) is safe to use while pregnant or breastfeeding. Certain factors, including the risks of not treating your condition during pregnancy, may determine whether ...

In June 2023, AMPH completed the acquisition of Baqsimi from Lilly for an upfront payment of $500 million and is required to pay $125 million on the completion of one year from the day of the closing ...

Lilly focused on delivering the Company's unprecedented pipeline of next-generation medicines to help patients Amphastar is the ideal company to continue Lilly's mission to help more people benefit ...